Publications by authors named "B Mahler-Araujo"

PTPRK is a receptor tyrosine phosphatase that is linked to the regulation of growth factor signalling and tumour suppression. It is stabilized at the plasma membrane by trans homophilic interactions upon cell-cell contact. PTPRK regulates cell-cell adhesion but is also reported to regulate numerous cancer-associated signalling pathways.

View Article and Find Full Text PDF

Objective: Coeliac disease (CD) diagnosis generally depends on histological examination of duodenal biopsies. We present the first study analysing the concordance in examination of duodenal biopsies using digitised whole-slide images (WSIs). We further investigate whether the inclusion of immunoglobulin A tissue transglutaminase (IgA tTG) and haemoglobin (Hb) data improves the interobserver agreement of diagnosis.

View Article and Find Full Text PDF

We identify the sodium leak channel non-selective protein (NALCN) as a key regulator of cancer metastasis and nonmalignant cell dissemination. Among 10,022 human cancers, NALCN loss-of-function mutations were enriched in gastric and colorectal cancers. Deletion of Nalcn from gastric, intestinal or pancreatic adenocarcinomas in mice did not alter tumor incidence, but markedly increased the number of circulating tumor cells (CTCs) and metastases.

View Article and Find Full Text PDF

Macrophages exhibit a spectrum of activation states ranging from classical to alternative activation. Alternatively, activated macrophages are involved in diverse pathophysiological processes such as confining tissue parasites, improving insulin sensitivity or promoting an immune-tolerant microenvironment that facilitates tumour growth and metastasis. Recently, the metabolic regulation of macrophage function has come into focus as both the classical and alternative activation programmes require specific regulated metabolic reprogramming.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare the effectiveness of 6 months versus 12 months of adjuvant trastuzumab in treating HER2-positive early breast cancer, with the main goal of determining if the shorter duration was as effective in preventing disease recurrence after 4 years.
  • Conducted as a Phase III randomized controlled trial across 152 NHS hospitals, it involved 4,088 patients who were randomly assigned to receive either 6 or 12 months of trastuzumab treatment alongside chemotherapy.
  • The primary outcome measured was disease-free survival, while secondary outcomes included overall survival, cost-effectiveness, and cardiac function, with an emphasis on showing that the shorter treatment duration remains within a non-inferiority
View Article and Find Full Text PDF